Kaneko K, Fujimori S, Kanbayashi T, Miyazawa Y, Kumakawa T, Fujii H, Miwa S, Kamatani N, Akaoka I
Second Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Int J Cancer. 1990 Jan 15;45(1):8-11. doi: 10.1002/ijc.2910450103.
The amount of polyamines in urine from patients with various neoplasms is larger than in normal subjects. We have determined the concentration of 5'-methylthioadenosine (MTA), a by-product of the polyamine biosynthesis, in patients with malignancies as well as normal subjects. Our studies indicate that the amount of MTA in urine from patients with leukemias and malignant lymphomas was higher than in normal subjects (p less than 0.005). Urine samples from patients with other malignancies contained normal amounts of MTA. The levels of blood MTA in patients with leukemias before treatment or in relapse was higher than in control subjects (p less than 0.005), while in patients with other malignancies and leukemia in remission, the levels were not different from control subjects. Peripheral blood MTA levels clearly decreased after effective chemotherapy. The measurement of MTA levels in urine and blood may not be as useful as polyamine assays for the detection of malignancies, but blood levels of MTA may be useful as an indicator of the efficacy of chemotherapy in leukemic patients.
各类肿瘤患者尿液中的多胺含量高于正常受试者。我们测定了恶性肿瘤患者以及正常受试者体内多胺生物合成的副产物5'-甲硫腺苷（MTA）的浓度。我们的研究表明，白血病和恶性淋巴瘤患者尿液中的MTA含量高于正常受试者（p<0.005）。其他恶性肿瘤患者的尿液样本中MTA含量正常。白血病患者治疗前或复发时血液中的MTA水平高于对照组（p<0.005），而其他恶性肿瘤患者和缓解期白血病患者的MTA水平与对照组无差异。有效化疗后外周血MTA水平明显下降。尿液和血液中MTA水平的测定对于恶性肿瘤的检测可能不如多胺检测有用，但血液中MTA水平可能作为白血病患者化疗疗效的指标。
